Target Interacting Protein Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T92477 | Target Info | |||
Target Name | Suppressor of cytokine signaling 3 (SOCS3) | ||||
Synonyms | STAT-induced STAT inhibitor 3; STAT induced STAT inhibitor 3; SSI3; SSI-3; SOCS-3; Cytokine-inducible SH2 protein 3; CIS3; CIS-3 | ||||
Target Type | Literature-reported Target | ||||
Gene Name | SOCS3 | ||||
UniProt ID |
Target Interacting Proteins | Top | ||||
---|---|---|---|---|---|
Cytokine receptors | [+] 1 Cytokine receptors | + | |||
Interacting Target Name | Erythropoietin Receptor (EPOR) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Full-length form; EPO-R | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [1] | |||
2 | Reconstituted Complex | [2] | |||
Ester hydrolases | [+] 1 Ester hydrolases | + | |||
Interacting Target Name | Protein-tyrosine phosphatase SHP-2 (PTPN11) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Tyrosine-protein phosphatase non-receptor type 11; SH-PTP3; SH-PTP2; SHPTP2; SHP-2; SHP2; PTP-2C; PTP2C; PTP-1D; Protein-tyrosine phosphatase SHP2; Protein-tyrosine phosphatase 2C; Protein-tyrosine phosphatase 1D | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [3] | |||
2 | Reconstituted Complex | [3] | |||
Kinases | [+] 5 Kinases | + | |||
Interacting Target Name | Janus kinase 2 (JAK-2) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Tyrosine-protein kinase JAK2 | ||||
Evidence Score (E-score) | 8 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [1] | |||
2 | Affinity Capture-Western | [4] | |||
3 | Affinity Capture-Western | [5] | |||
4 | Affinity Capture-Western | [6] | |||
5 | Affinity Capture-Western | [7] | |||
6 | Biochemical Activity | [8] | |||
7 | Reconstituted Complex | [9] | |||
8 | Yeast two hybrid | [10] | |||
Interacting Target Name | Epidermal growth factor receptor (EGFR) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Epidermal growth factor receptor variant III; Proto-oncogene c-ErbB-1 variant III; Receptor tyrosine-protein kinase erbB-1 variant III; EGFR variant III; ERBB variant III; ERBB1 variant III; HER1 variant III | ||||
Evidence Score (E-score) | 4 Experimental Evidences | + | |||
1 | Affinity Capture-Luminescence | [11] | |||
2 | Affinity Capture-Western | [12] | |||
3 | Protein-Fragment Complementation Assay | [11] | |||
4 | Yeast two hybrid | [13] | |||
Interacting Target Name | Focal adhesion kinase 1 (FAK) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Protein-tyrosine kinase 2; Protein phosphatase 1 regulatory subunit 71; PPP1R71; pp125FAK; p125FAK; FRNK; Focal adhesion kinase-related nonkinase; FAK1; FADK 1; FADK | ||||
Evidence Score (E-score) | 4 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [14] | |||
2 | Far Western | [15] | |||
3 | Reconstituted Complex | [15] | |||
4 | Yeast two hybrid | [16] | |||
Interacting Target Name | Janus kinase 1 (JAK-1) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Tyrosine-protein kinase JAK1; JAK1B; JAK1A | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [17] | |||
2 | Biochemical Activity | [18] | |||
Interacting Target Name | Focal adhesion kinase 2 (PTK2B) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Related adhesion focal tyrosine kinase; RAFTK; PYK2; Protein-tyrosine kinase 2-beta; Proline-rich tyrosine kinase 2; FAK2; FADK 2; Cell adhesion kinase beta; Calcium-regulated non-receptor proline-rich tyrosine kinase; Calcium-dependent tyrosine kinase; CAK-beta; CAKB; CADTK | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [19] | |||
2 | Yeast two hybrid | [10] | |||
Other proteins | [+] 1 Other proteins | + | |||
Interacting Protein Name | Elongin-C (ELOC) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | SIII; eloC | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [20] | |||
2 | Affinity Capture-Western | [21] | |||
3 | Reconstituted Complex | [22] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem. 2000 Sep 22;275(38):29338-47. | ||||
REF 2 | A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem. 2002 May;269(10):2516-26. | ||||
REF 3 | SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem. 2003 Jan 3;278(1):661-71. | ||||
REF 4 | Suppressor of cytokine signaling-3 Provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology. 2005 Feb;146(2):579-88. | ||||
REF 5 | The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells. Oncogene. 2001 Feb 15;20(7):849-58. | ||||
REF 6 | Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells. 1999 Jun;4(6):339-51. | ||||
REF 7 | SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene. 2009 Aug 27;28(34):3069-80. | ||||
REF 8 | Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates. Growth Factors. 2014 Feb;32(1):1-10. | ||||
REF 9 | Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity. 2012 Feb 24;36(2):239-50. | ||||
REF 10 | Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun. 1997 Oct 20;239(2):439-46. | ||||
REF 11 | The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells. Nat Methods. 2014 May;11(5):585-92. | ||||
REF 12 | Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem. 2002 Aug 23;277(34):30716-23. | ||||
REF 13 | In silico prediction of physical protein interactions and characterization of interactome orphans. Nat Methods. 2015 Jan;12(1):79-84. | ||||
REF 14 | SOCS3 protein developmentally regulates the chemokine receptor CXCR4-FAK signaling pathway during B lymphopoiesis. Immunity. 2007 Nov;27(5):811-23. | ||||
REF 15 | Negative regulation of FAK signaling by SOCS proteins. EMBO J. 2003 Oct 1;22(19):5036-46. | ||||
REF 16 | A proteome-scale map of the human interactome network. Cell. 2014 Nov 20;159(5):1212-1226. | ||||
REF 17 | Thyrotropin induces SOCS-1 (suppressor of cytokine signaling-1) and SOCS-3 in FRTL-5 thyroid cells. Mol Endocrinol. 2000 Mar;14(3):440-8. | ||||
REF 18 | SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol. 1999 Jul;19(7):4980-8. | ||||
REF 19 | SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro. BMC Cancer. 2008 May 28;8:150. | ||||
REF 20 | Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 2007 Jan;21(1):217-22. | ||||
REF 21 | VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 2004 Dec 15;18(24):3055-65. | ||||
REF 22 | Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem. 2003 Aug 22;278(34):31972-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.